Nipruss (Sodium Nitroprusside Dihydrate)

Sodium nitroprusside releases nitric oxide when it enters the bloodstream. The nitric oxide stimulates soluble guanylate cyclase, increasing cyclic GMP levels in vascular smooth muscle. Elevated cyclic GMP leads to smooth‑muscle relaxation, causing dose‑dependent dilation of both arterioles and veins, which reduces preload, afterload, and systemic blood pressure.

The dosing of Nipruss is individualized and must be determined by the prescribing clinician. Infusion rates are titrated to the patient’s hemodynamic response, with continuous blood‑pressure monitoring to achieve the desired therapeutic target while avoiding excessive hypotension.

Safety data for sodium nitroprusside in pregnancy and lactation are limited. It should only be used when the potential maternal benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with obstetric specialists.

To request Nipruss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Compared with agents such as nitroglycerin or hydralazine, sodium nitroprusside provides a more rapid and controllable reduction in both arterial and venous pressure, making it especially useful in emergencies and intra‑operative settings. However, it requires careful monitoring for cyanide accumulation, a risk that is less prominent with many alternative vasodilators.

Nipruss should be stored at controlled room temperature, ideally below 25 °C, in its original container. Protect the solution from direct light, moisture and extreme temperature fluctuations. Once prepared, the infusion should be used promptly and any unused portion discarded according to local regulations.

Nipruss is supplied as an intravenous solution and is administered by continuous infusion through a calibrated infusion pump. The infusion rate is adjusted based on real‑time blood‑pressure measurements, and the drug is typically diluted in a compatible carrier fluid before administration.

The most critical adverse events include cyanide toxicity, which can lead to metabolic acidosis and organ dysfunction, severe hypotension causing inadequate tissue perfusion, and cardiac arrhythmias. Early detection through clinical monitoring and laboratory testing is essential to mitigate these risks.

Nipruss is contraindicated in patients with known hypersensitivity to sodium nitroprusside or its excipients, those with severe anemia, uncompensated hypoxia, or significant vitamin B12 deficiency that impairs cyanide metabolism. Caution is also advised in patients with pre‑existing methemoglobinemia or severe renal/hepatic impairment.